A Phase 3 interventional study of Gabapentin and Gabapentin in Transient Insomnia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-02.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing gabapentin in Sleep Initiation and Maintenance Disorders — none open to participants now, none under way, none of them phase 3. Gabapentin · Sleep Initiation and Maintenance Disorders.
Among the 14 studies testing gabapentin in Sleep Initiation and Maintenance Disorders, this one is the 7th largest by enrollment, is one of 5 that started in 2004, is one of 9 in phase 3, and was the 3rd registered.
2,729 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 731 are open to participants now.
Browse Sleep Initiation and Maintenance Disorders studies →None of the 14 studies testing gabapentin in Sleep Initiation and Maintenance Disorders is open now. The open studies under Sleep Initiation and Maintenance Disorders, anywhere →
Gabapentin: first FDA approval 1993 (NEURONTIN). What it is approved for, and how studies give it, is on its page →
Of the 390 Sleep Initiation and Maintenance Disorders studies recruiting now, 153 (39%) set no upper age limit and 207 (53%) stop at 75 or younger; 59 take children under 18; 109 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 5 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 309 is above the median of 68 across 2,356 interventional studies indexed under Sleep Initiation and Maintenance Disorders.
Median enrollment 283 across the 14 interventional studies. Of the 14 that completed or were terminated, 2 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 14 have an industry lead sponsor. The 6 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
Viatris Inc. has 9 studies filed under Sleep Initiation and Maintenance Disorders — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing gabapentin in Sleep Initiation and Maintenance Disorders, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the effect of gabapentin as compared to placebo on sleep in subjects with transient insomnia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Gabapentin
Drug: Gabapentin
Drug: Placebo
Gabapentin 250 mg oral capsule 30 minutes prior to bedtime
Gabapentin 500 mg oral capsule 30 minutes prior to bedtime
Matched placebo 30 minutes prior to bedtime
Latency to persistent sleep as measured by polysomnography
Time frame: Hour +8
Subjective wake after sleep onset
Time frame: Hour +8
Subjective total sleep time
Time frame: Hour +8
Subjective assessment of sleep refreshment
Time frame: Hour +8
Subjective assessment of sleep quality
Time frame: Hour +8
Stanford Sleepiness Scale
Time frame: Hour +13
Karolinska Sleep Diary-Sleep (KSD) Quality Index
Time frame: Hour +8
KSD individual scores
Time frame: Hour +8
Digit Symbol Substitution Test
Time frame: Hour +8
Latency to REM sleep
Time frame: Hour +8
Number of awakenings
Time frame: Hour +8
Wake after sleep onset
Time frame: Hour +8
Total wake time plus Stage 1 sleep
Time frame: Hour +8
Total sleep time
Time frame: Hour +8
Sleep efficiency
Time frame: Hour +8
Percent of Stages 1, 2, 3, 4 (non-REM) and REM sleep
Time frame: Hour +8
Buschke Selective Reminding Test (immediate recall score, long term storage score, total number of intrusions, delayed recall score)
Time frame: Hour +8
Vital signs
Time frame: Hour +8
Adverse events
Time frame: Hour +13
Sleep onset latency
Time frame: Hour +8
Percent slow wave sleep (Stages 3&4 combined)
Time frame: Hour +8
Subjective sleep latency
Time frame: Hour +8
Subjective number of awakenings
Time frame: Hour +8
The record gives a start of Oct 2004 and a completion of Nov 2004. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gabapentin
Sleep Initiation and Maintenance Disorders →
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →